Table 1 Baseline characteristics of patients with hematologic and lymphatic system adverse events related to chimeric antigen receptor T-Cell therapy
Clinical characteristics | Tisagenlecleucel (N = 545) | Axicabtagene ciloleucel (N = 790) | Brexucabtagene toleucel (N = 97) | Lisocabtagene maraleucel (N = 30) | Idecabtagene vicleucel N=(96) | Ciltacabtagene autoleucel (N = 42) | Total (N = 1,600) |
|---|---|---|---|---|---|---|---|
Gender | |||||||
 Female | 202(37.1%) | 302(38.2%) | 23(23.7%) | 13(43.3%) | 42(43.8%) | 15(35.7%) | 597(37.3%) |
 Male | 296(54.3%) | 404(51.1%) | 72(74.2%) | 17(56.7%) | 40(41.7%) | 14(33.3%) | 843(52.7%) |
 Missing | 47(8.6%) | 84(10.6%) | 2(2.1%) | 0(0%) | 14(14.6%) | 13(31.0%) | 160(10.0%) |
Age in years, median(IQR) | 21(12–58) | 60(49–67) | 63(55.75–69.25) | 65.5(56.5–70) | 66(62–72) | 58.5(54.25-66) | 57(32–67) |
Age group | |||||||
 < 18 years | 189(34.7%) | 2(0.3%) | 1(1.0%) | 0(0%) | 0(0%) | 0(0%) | 192(12.0%) |
 18–65 years | 174(31.9%) | 423(53.5%) | 41(42.3%) | 14(46.7%) | 29(30.2%) | 15(35.7%) | 696(43.5%) |
 ≥ 65 years | 82(15.0%) | 221(28.0%) | 38(39.2%) | 16(53.3%) | 42(43.8%) | 7(16.7%) | 406(25.4%) |
 Missing | 100(18.3%) | 144(18.2%) | 17(17.5%) | 0(0%) | 25(26.0%) | 20(47.6%) | 306(19.1%) |
Country | |||||||
 US | 355(65.1%) | 366(46.3%) | 54(55.7%) | 17(56.7%) | 55(57.3%) | 34(81.0%) | 881(55.1%) |
 JP | 31(5.7%) | 2(0.3%) | 0(0%) | 12(40.0%) | 4(4.2%) | 0(0%) | 49(3.1%) |
 AU | 26(4.8%) | 6(0.8%) | 0(0%) | 0(0%) | 0(0%) | 1(2.4%) | 33(2.1%) |
 FR | 26(4.8%) | 73(9.2%) | 13(13.4%) | 0(0%) | 21(21.9%) | 4(9.5%) | 137(8.6%) |
 ES | 18(3.3%) | 67(8.5%) | 2(2.1%) | 0(0%) | 0(0%) | 2(4.8%) | 89(5.6%) |
 CN | 0(0%) | 99(12.5%) | 2(2.1%) | 0(0%) | 0(0%) | 1(2.4%) | 102(6.4%) |
 DE | 11(2.0%) | 57(7.2%) | 6(6.2%) | 0(0%) | 2(2.1%) | 0(0%) | 76(4.8%) |
 IT | 5(0.9%) | 29(3.7%) | 6(6.2%) | 0(0%) | 0(0%) | 0(0%) | 40(2.5%) |
 Other country | 64(11.7%) | 91(11.5%) | 14(14.4%) | 1(3.3%) | 14(14.6%) | 0(0%) | 184(11.5%) |
 Missing | 9(1.7%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 9(0.6%) |
Reporter type | |||||||
 Healthcare professional | 466(85.5%) | 725(91.8%) | 88(90.7%) | 28(93.3%) | 76(79.2%) | 31(73.8%) | 1414(88.4%) |
 Consumer | 70(12.8%) | 42(5.3%) | 1(1.0%) | 0(0%) | 15(15.6%) | 8(19.0%) | 136(8.5%) |
 Missing | 9(1.7%) | 23(2.9%) | 8(8.2%) | 2(6.7%) | 5(5.2%) | 3(7.1%) | 50(3.1%) |
Outcome | |||||||
 Death | 98(18.0%) | 110(13.9%) | 18(18.6%) | 8(26.7%) | 5(5.2%) | 5(11.9%) | 244(15.3%) |
 Disability | 1(0.2%) | 6(0.8%) | 2(2.1%) | 0(0%) | 2(2.1%) | 0(0%) | 11(0.7%) |
 Hospitalization | 115(21.1%) | 218(27.6%) | 34(35.1%) | 8(26.7%) | 21(21.9%) | 11(26.2%) | 407(25.4%) |
 Life-threatening | 46(8.4%) | 23(2.9%) | 3(3.1%) | 1(3.3%) | 1(1.0%) | 1(2.4%) | 75(4.7%) |
 Other events | 277(50.8%) | 411(52.0%) | 39(40.2%) | 11(36.7%) | 66(68.8%) | 24(57.1%) | 828(51.8%) |
 Missing | 8(1.5%) | 22(2.8%) | 1(1.0%) | 2(6.7%) | 1(1.0%) | 1(2.4%) | 35(2.2%) |